MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 74 filers reported holding MIRUM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,096,444 | +279.5% | 224,571 | +210.7% | 0.00% | +100.0% |
| Q2 2023 | $1,869,987 | +47.6% | 72,284 | +37.1% | 0.00% | – |
| Q1 2023 | $1,266,791 | +25.5% | 52,739 | +1.8% | 0.00% | – |
| Q4 2022 | $1,009,769 | -4.6% | 51,783 | +2.8% | 0.00% | – |
| Q3 2022 | $1,058,000 | +27.8% | 50,353 | +18.4% | 0.00% | – |
| Q2 2022 | $828,000 | +142.1% | 42,511 | +174.3% | 0.00% | – |
| Q1 2022 | $342,000 | +45.5% | 15,500 | +5.5% | 0.00% | – |
| Q4 2021 | $235,000 | -19.8% | 14,696 | 0.0% | 0.00% | – |
| Q3 2021 | $293,000 | -77.5% | 14,696 | -80.5% | 0.00% | – |
| Q2 2021 | $1,304,000 | -13.8% | 75,418 | -1.2% | 0.00% | -100.0% |
| Q1 2021 | $1,513,000 | +45.5% | 76,317 | +28.1% | 0.00% | – |
| Q4 2020 | $1,040,000 | -7.8% | 59,553 | +1.8% | 0.00% | -100.0% |
| Q3 2020 | $1,128,000 | +277.3% | 58,487 | +281.4% | 0.00% | – |
| Q2 2020 | $299,000 | +91.7% | 15,333 | +38.4% | 0.00% | – |
| Q1 2020 | $156,000 | – | 11,078 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
| NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
| BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
| Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
| BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
| Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
| Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
| Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
| Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |